This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Antipsychotic Polypharmacy, Part 1: Therapeutic Option or Dirty Little Secret?

Stephen M. Stahl

Published: July 1, 1999

Article Abstract

The 3 new antipsychotics—risperidone, olanzapine, and quetiapine—are transforming the treatment of schizophrenia and other psychotic illnesses. These new atypical antipsychotic agents have now replaced so-called conventional antipsychotics such as haloperidol and chlorpromazine because clinical trials confirm that atypical antipsychotics have a better safety and efficacy profile than conventional antipsychotics. Clinical experience reveals that some patients respond better to one of these agents than to another, sometimes dramatically.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 60

Quick Links: